TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16825680

Group type: COMPARATOR
Intervention: Low-LA diet (3% of energy from LA, 0.4% of energy from ALA, ALA-to-LA ratio = 1:7)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-ALA diet (7% of energy from LA, 1.1% of energy from ALA, ALA-to-LA ratio = 1:7)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Control diet (7% of energy from LA, 0.4% of energy from ALA, ALA-to-LA ratio = 1:19)
Number of subjects: 29
Study: 15552357

Group type: EXPERIMENTAL
Intervention: Cues receiving strong inputs from other associates (e.g., car)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attending to another task during or after study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Receiving implicit test instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disruptions to retrieval of context features
Number of subjects: 0
Study: 11172852

Group type: EXPERIMENTAL
Intervention: Tibolone plus GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Placebo plus GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66

Group type: COMPARATOR
Intervention: GnRH analogue (leuprolide acetate and iron tablets)
Number of subjects: 66
Study: 9525541

Group type: EXPERIMENTAL
Intervention: Long-term anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational data collection
Number of subjects: 0
Study: 7837950

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD) therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with hypocaloric diet (AEX+HD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (HD vs AEX+HD)
Number of subjects: 30
Study: 3287534

Group type: EXPERIMENTAL
Intervention: Aminophylline (1-2 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29668352

Group type: EXPERIMENTAL
Intervention: Triple therapy (fluticasone furoate 100 μg, umeclidinium 62.5 μg, vilanterol 25 μg)
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Fluticasone furoate-vilanterol (100 μg and 25 μg)
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Umeclidinium-vilanterol (62.5 μg and 25 μg)
Number of subjects: 10355

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Umeclidinium-vilanterol
Number of subjects: 10355
Study: 27411768

Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 25054390

Group type: EXPERIMENTAL
Intervention: TEA (Thoracic Epidural Analgesia)
Number of subjects: 30
Study: 22585689

Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH) - 16 adjuvant intravesical instillations after preimmunization
Number of subjects: 283

Group type: COMPARATOR
Intervention: Mitomycin (MM) - 11 adjuvant intravesical instillations
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Mitomycin (MM)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Delayed-type hypersensitivity (DTH) response
Number of subjects: 283
Study: 20079572

Group type: EXPERIMENTAL
Intervention: Procutase (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% silver sulphadiazine (SSD) (Group A)
Number of subjects: 0
Study: 18410464

Group type: EXPERIMENTAL
Intervention: Bepotastine (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16822134

Group type: EXPERIMENTAL
Intervention: Attractor tap preceding attractee tap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attractor tap and attractee tap sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaze direction and concurrent auditory temporal information
Number of subjects: 0
Study: 12798894

Group type: EXPERIMENTAL
Intervention: P1 medium supplemented with 0.5 mg/mL hyaluronic acid for 5‐10 min before intrauterine transfer
Number of subjects: 80

Group type: COMPARATOR
Intervention: P1 medium containing 10% synthetic serum substitute (SSS)
Number of subjects: 80
Study: 11004052

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 3.75 IU/mL
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 7.5 IU/mL
Number of subjects: 714

Group type: COMPARATOR
Intervention: No hyaluronidase
Number of subjects: 714
Study: 8770965

Group type: EXPERIMENTAL
Intervention: Enalaprilat (10 mg i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exogenous angiotensin II infusion
Number of subjects: 9
Study: 1628410

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nicardipine slow release 40 mg twice daily
Number of subjects: 12
Study: 6230629

Group type: EXPERIMENTAL
Intervention: Clodronate (Dichloromethylene diphosphonate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31606364

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid antagonists (MRAs) therapy maintained or increased during hospitalization
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) maintained or increased during hospitalization
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Down-titration of MRAs during hospitalization
Number of subjects: 1589
Study: 30307304

Group type: EXPERIMENTAL
Intervention: L-arginine (7 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (EX-PLA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine (7 g) alone (L-ARG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EX-LARG (L-arginine + exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: EX-PLA (Placebo + exercise)
Number of subjects: 20
Study: 26661687

Group type: EXPERIMENTAL
Intervention: HM (Home Monitoring)
Number of subjects: 1339
Study: 25228130

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion during surgery (n = 33)
Number of subjects: 65
Study: 22410137

Group type: EXPERIMENTAL
Intervention: 4-month daily rifampicin regimen (4R); n = 190
Number of subjects: 373

Group type: COMPARATOR
Intervention: 6-month daily isoniazid regimen (6H); n = 183
Number of subjects: 373
Study: 20858783

Group type: EXPERIMENTAL
Intervention: Incomplete excavation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Complete excavation
Number of subjects: 28
Study: 19111163

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with alum-formulated recombinant human GAD65
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15879822

Group type: EXPERIMENTAL
Intervention: Active electromagnetic therapy (15 minutes at 10 Hz followed by 15 minutes at 50 Hz, twice weekly for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 21
Study: 12743130

Group type: EXPERIMENTAL
Intervention: Cisplatin-based intraperitoneal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cisplatin
Number of subjects: 0
Study: 10562927

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Raynaud's group (40 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DPI associated with provocation test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plethysmographic wave
Number of subjects: 40
Study: 8867677

Group type: EXPERIMENTAL
Intervention: Monthly replacement schedule
Number of subjects: 12

Group type: COMPARATOR
Intervention: Three monthly replacement schedule
Number of subjects: 12
Study: 1987395

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no cerebrospinal fluid drainage)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension
Number of subjects: 98
Study: 3986081

Group type: EXPERIMENTAL
Intervention: 5 mg/kg doses of caffeine as an aqueous oral solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg/kg doses of caffeine as an intravenous infusion
Number of subjects: 12
Study: 30851630

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg)
Number of subjects: 24
Study: 29253351

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 27272130

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (PA)
Number of subjects: 20266

Group type: EXPERIMENTAL
Intervention: Occupational activity
Number of subjects: 20266

Group type: EXPERIMENTAL
Intervention: Commuting physical activity
Number of subjects: 20266

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 20266
Study: 25149197

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low-fat/low-calorie diet
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: FPQ diet preference
Number of subjects: 105
Study: 21947604

Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 25
Study: 20862933

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with speech therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Speech therapy only (Control)
Number of subjects: 61
Study: 22795211

Group type: EXPERIMENTAL
Intervention: d-serine 2 g/d
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 15593389

Group type: EXPERIMENTAL
Intervention: Increased expression of aquaporin-4 (AQP4)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AQP4 immunoreactivity around astrocytomas, ganglioglioma, and metastatic adenocarcinoma
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AQP4 immunoreactivity in centers of astrocytomas and ganglioglioma
Number of subjects: 19
Study: 12704001

Group type: EXPERIMENTAL
Intervention: CAF regimen (Cytoxan 600 mg/m(2), Adriamycin 60 mg/m(2), 5‐FU 600 mg/m(2))
Number of subjects: 117

Group type: COMPARATOR
Intervention: TP regimen (paclitaxel 135 mg/m(2), cisplatin 60 mg/m(2))
Number of subjects: 117
Study: 9585024

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) as a mass screening tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) and polypectomy
Number of subjects: 0
Study: 8607102

Group type: EXPERIMENTAL
Intervention: Intermittent regional therapy with 20 mg rt-PA for 4 h each day
Number of subjects: 137

Group type: COMPARATOR
Intervention: Systemic thrombolytic therapy with 20 mg rt-PA for 4 h each day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both interventions (intermittent regional and systemic thrombolytic therapy)
Number of subjects: 137
Study: 2776167

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 1103743

Group type: EXPERIMENTAL
Intervention: Topically applied griseofulvin in alcohol solution
Number of subjects: 0
Study: 31840273

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 46
Study: 29884522

Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE) 2×/week for 24 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Square-stepping exercise (SSE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 28216860

Group type: EXPERIMENTAL
Intervention: Pilates training (1 hour, 3 sessions/week for 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: McKenzie training (1 hour/day for 20 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 26091917

Group type: EXPERIMENTAL
Intervention: ICBT‐i
Number of subjects: 148

Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 148
Study: 22108512

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study: 21226754

Group type: EXPERIMENTAL
Intervention: Nurse-administered minimal psychological intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study: 18641169

Group type: EXPERIMENTAL
Intervention: Technology enhanced viewing condition (included additional Web‐support)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Standard viewing condition
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Both conditions (Technology enhanced and Standard)
Number of subjects: 723
Study: 16635651

Group type: EXPERIMENTAL
Intervention: Methamphetamine use (MAMP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (drug-free subjects)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MAMP use
Number of subjects: 200
Study: 14528134

Group type: EXPERIMENTAL
Intervention: Health Buddy telehealth communication device
Number of subjects: 90

Group type: COMPARATOR
Intervention: Telephonic disease management
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional home management strategies (telephonic, home visit)
Number of subjects: 90
Study: 10751262

Group type: COMPARATOR
Intervention: Levodopa-medicated patients with advanced PD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unmedicated patients with early PD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 48
Study: 9216152

Group type: EXPERIMENTAL
Intervention: Neural classifier using flow cytometry data
Number of subjects: 170
Study: 1358004

Group type: EXPERIMENTAL
Intervention: Atracurium 0.50 mg.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.10 mg.kg‐1
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no tetanic stimulation)
Number of subjects: 56
Study: 3877288

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 12
Study: 31980826

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 24
Study: 29368802

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice (BRJ) containing 12.3 ± 0.8 mmol of NO3‐
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (beetroot juice devoid of NO3‐)
Number of subjects: 20
Study: 27515333

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 473

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 473
Study: 25258045

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and exercise interventions
Number of subjects: 222
Study: 22897617

Group type: EXPERIMENTAL
Intervention: Autologous noncultured epidermal cell suspension (NCES)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Suction blister epidermal grafting (SBEG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both NCES and SBEG
Number of subjects: 41
Study: 20618316

Group type: EXPERIMENTAL
Intervention: Computer analysis by the Omniview‐SisPorto 3.5 system (study group n = 104)
Number of subjects: 204

Group type: COMPARATOR
Intervention: No analysis (control group n = 100)
Number of subjects: 204
Study: 18346604

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% + morphine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% + morphine
Number of subjects: 18
Study: 15892618

Group type: EXPERIMENTAL
Intervention: Imatinib mesilate (Gleevec) for metastatic gastrointestinal stromal tumors (GISTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa) for esophageal and colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva) for esophageal, colorectal, hepatocellular, biliary carcinoma, and pancreatic cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) for irinotecan resistant colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) for metastatic colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) in combination with gemcitabine for pancreatic cancer
Number of subjects: 0
Study: 12009370

Group type: EXPERIMENTAL
Intervention: One transcervical insertion of 252 mg of quinacrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two transcervical insertions of 252 mg of quinacrine
Number of subjects: 100
Study: 10544425

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive physical education activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directed physical education activities
Number of subjects: 0
Study: 7775186

Group type: COMPARATOR
Intervention: 75 mg meperidine with 25 mg promethazine IM
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5 mg dihydroergotamine with 10 mg metoclopramide IV
Number of subjects: 27
Study: 2190629

Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg oral dose
Number of subjects: 12
Study: 495064

Group type: EXPERIMENTAL
Intervention: Smith-Petersen osteosynthesis
Number of subjects: 197

Group type: COMPARATOR
Intervention: Sliding-nail-plate osteosynthesis
Number of subjects: 197
Study: 30025177

Group type: EXPERIMENTAL
Intervention: 4.5 g of intravenous MgSO4 (low-dose group)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 9 g of intravenous MgSO4 (high-dose group)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Serum saline infusion (placebo group)
Number of subjects: 450
Study: 26763665

Group type: EXPERIMENTAL
Intervention: Variolink II (V)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Superbond (S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (young teeth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (geriatric teeth)
Number of subjects: 60
Study: 27278926

Group type: EXPERIMENTAL
Intervention: Raw Beet Juice (RBJ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cooked Beet (CB)
Number of subjects: 24
Study: 24848793

Group type: EXPERIMENTAL
Intervention: Synbiotic capsules containing 200 million of seven strains of friendly bacteria plus fructo‐oligosaccharide, twice a day for 28 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 28 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Synbiotic capsules
Number of subjects: 38
Study: 23091139

Group type: EXPERIMENTAL
Intervention: Microbial phytase (500 FTU/kg) with low nonphytate P (0.18%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Microbial phytase (500 FTU/kg) with high calcium (0.77%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: High calcium (0.77%) and low nonphytate P (0.18%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low calcium (0.37%) and high nonphytate P (0.32%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low calcium (0.37%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Increasing dietary calcium
Number of subjects: 144
Study: 19084376

Group type: EXPERIMENTAL
Intervention: Enriched milk (500 mL/d)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Skimmed milk (500 mL/d)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Semi-skimmed milk (500 mL/d)
Number of subjects: 297
Study: 17445067

Group type: EXPERIMENTAL
Intervention: 900 MHz RF exposure (2W)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1800 MHz RF exposure (1W)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 30
Study: 15645325

Group type: EXPERIMENTAL
Intervention: Monitor position A (frontal at eye level)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Monitor position B (frontal in height of the operating field)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Monitor position C (45 degrees to the right side at eye level)
Number of subjects: 18
Study: 11990912

Group type: EXPERIMENTAL
Intervention: Single 400-mg fluconazole dose
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 9226511

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg administered nightly with gonadotropin therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gonadotropin therapy without dexamethasone (control group)
Number of subjects: 42
Study: 7960733

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 64
Study: 2890509

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (three times)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31017381

Group type: EXPERIMENTAL
Intervention: Measuring wheel during the 6MWT
Number of subjects: 317

Group type: COMPARATOR
Intervention: Conventional walking during the 6MWT
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Students from sports schools
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Height, post-test heart rate, male sex, measuring wheel
Number of subjects: 317
Study: 30027281

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) only
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: IPC + low-molecular-weight (LMW) heparin sodium
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: IPC + LMW heparin sodium
Number of subjects: 682

Group type: COMPARATOR
Intervention: IPC only
Number of subjects: 682
Study: 27838692

Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapor ablation (BTVA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 24661535

Group type: EXPERIMENTAL
Intervention: Active games intervention for 10 months, including encouragement to play.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group receiving active games after the intervention period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active games intervention
Number of subjects: 0
Study: 22178004

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High Carbohydrate, High Fiber (HCHF) diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 84